| Nov 6 |
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
|
| Oct 16 |
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
|
| Oct 9 |
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...
|
| Sep 26 |
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
|
| Sep 24 |
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
| Sep 19 |
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
|
| Sep 9 |
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
|
| Aug 28 |
HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
| Jul 29 |
HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
|
| Jul 5 |
Hutchmed gains as Ipsen-partnered lymphoma drug undergoes review in China
|
